Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Forges Collaboration with UC Davis to Validate miRNA Profile for Bladder Cancer

Premium

Rosetta Genomics this week announced that it is collaborating with the University of California, Davis, to develop and validate a microRNA profile for muscle-invasive bladder cancer that will help predict how patients will respond to neoadjuvant chemotherapy.

“A secondary goal of the study is to understand the mechanism by which differentially expressed microRNAs mediate chemosensitivity,” Rosetta said.

“Predicting responses to chemotherapy is becoming increasingly important with advances in oncology and
the introduction of molecularly targeted cancer drugs,” Rosetta President and CEO Kenneth Berlin said in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.